Literature DB >> 23349315

Inactivation or loss of TTP promotes invasion in head and neck cancer via transcript stabilization and secretion of MMP9, MMP2, and IL-6.

Elizabeth A Van Tubergen1, Rajat Banerjee, Min Liu, Robert Vander Broek, Emily Light, Shiuhyang Kuo, Stephen E Feinberg, Amanda L Willis, Gregory Wolf, Thomas Carey, Carol Bradford, Mark Prince, Francis P Worden, Keith L Kirkwood, Nisha J D'Silva.   

Abstract

PURPOSE: Invasion is the critical step in progression of a precancerous lesion to squamous cell carcinoma of the head and neck (HNSCC). Invasion is regulated by multiple proinflammatory mediators. Tristetraprolin (TTP) is an mRNA-degrading protein that regulates multiple proinflammatory mediators. TTP may serve as an excellent treatment target. Rap1 is a ras-like oncoprotein that induces critical signaling pathways. In this study, the role of rap1 in TTP-mediated invasion was investigated. EXPERIMENTAL
DESIGN: Using complementary approaches, we modulated TTP and altered expression of interleukin (IL)-6 and matrix metalloproteinase (MMP) 2/9, which were quantified by ELISA and zymogram. Invasion was evaluated in vitro using the oral-cancer-equivalent (OCE) three-dimensional model and in vivo in the chick chorioallantoic membrane (CAM). The role of rap1 and p38 were established using knockdown strategies.
RESULTS: Downregulation of TTP significantly increased invasion via secretion of MMP9/2 and IL-6. In the novel OCE and CAM invasion models of HNSCC, cells with downregulated TTP destroyed the basement membrane to invade the underlying connective tissue. Rap1 induces p38 mitogen-activated protein kinase (p38)-mediated inactivation of TTP. Inactive TTP enhances transcript stability via binding to the 3'-untranslated region (UTR). High IL-6 and MMP9 are prognostic for poor clinical outcomes in patients with HNSCC.
CONCLUSIONS: Targeting the rap1-p38-TTP cascade is an attractive novel treatment strategy in HNSCC to concurrently suppress multiple mediators of invasion. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23349315      PMCID: PMC3594656          DOI: 10.1158/1078-0432.CCR-12-2927

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  45 in total

Review 1.  The roles of TTP and BRF proteins in regulated mRNA decay.

Authors:  Sandhya Sanduja; Fernando F Blanco; Dan A Dixon
Journal:  Wiley Interdiscip Rev RNA       Date:  2011 Jan-Feb       Impact factor: 9.957

Review 2.  Control of cytokine mRNA expression by RNA-binding proteins and microRNAs.

Authors:  V Palanisamy; A Jakymiw; E A Van Tubergen; N J D'Silva; K L Kirkwood
Journal:  J Dent Res       Date:  2012-02-01       Impact factor: 6.116

3.  Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability.

Authors:  E Carballo; W S Lai; P J Blackshear
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

Review 4.  Biomarkers of epithelial-mesenchymal transition in squamous cell carcinoma.

Authors:  C S Scanlon; E A Van Tubergen; R C Inglehart; N J D'Silva
Journal:  J Dent Res       Date:  2012-11-05       Impact factor: 6.116

5.  Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury.

Authors:  Praveen Anand; Ravikiran Shenoy; Joanne E Palmer; Amanda J Baines; Robert Y K Lai; Jonathan Robertson; Nick Bird; Thor Ostenfeld; Boris A Chizh
Journal:  Eur J Pain       Date:  2011-05-14       Impact factor: 3.931

6.  NADPH oxidase-derived superoxide destabilizes lipopolysaccharide-induced interleukin 8 mRNA via p38, extracellular signal-regulated kinase mitogen-activated protein kinase, and the destabilizing factor tristetraprolin.

Authors:  Imad Al Ghouleh; Sheldon Magder
Journal:  Shock       Date:  2012-04       Impact factor: 3.454

7.  Tristetraprolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma.

Authors:  Elizabeth Van Tubergen; Robert Vander Broek; Julia Lee; Gregory Wolf; Thomas Carey; Carol Bradford; Mark Prince; Keith L Kirkwood; Nisha J D'Silva
Journal:  Cancer       Date:  2011-01-10       Impact factor: 6.860

8.  Tristetraprolin regulates interleukin-6 expression through p38 MAPK-dependent affinity changes with mRNA 3' untranslated region.

Authors:  Wenpu Zhao; Min Liu; Nisha J D'Silva; Keith L Kirkwood
Journal:  J Interferon Cytokine Res       Date:  2011-04-03       Impact factor: 2.607

9.  A synonymous polymorphism of the Tristetraprolin (TTP) gene, an AU-rich mRNA-binding protein, affects translation efficiency and response to Herceptin treatment in breast cancer patients.

Authors:  Paola Griseri; Christine Bourcier; Corinne Hieblot; Khadija Essafi-Benkhadir; Emmanuel Chamorey; Christian Touriol; Gilles Pagès
Journal:  Hum Mol Genet       Date:  2011-08-29       Impact factor: 6.150

10.  Chick chorioallantoic membrane (CAM) assay as an in vivo model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis.

Authors:  Noor A Lokman; Alison S F Elder; Carmela Ricciardelli; Martin K Oehler
Journal:  Int J Mol Sci       Date:  2012-08-10       Impact factor: 6.208

View more
  38 in total

1.  The G protein-coupled receptor GALR2 promotes angiogenesis in head and neck cancer.

Authors:  Rajat Banerjee; Elizabeth A Van Tubergen; Christina S Scanlon; Robert Vander Broek; Joel P Lints; Min Liu; Nickole Russo; Ronald C Inglehart; Yugang Wang; Peter J Polverini; Keith L Kirkwood; Nisha J D'Silva
Journal:  Mol Cancer Ther       Date:  2014-02-25       Impact factor: 6.261

2.  Post-transcriptional regulation of MMP2 mRNA by its interaction with miR-20a and Nucleolin in breast cancer cell lines.

Authors:  Sayantani Das; Soumasree De; Sumita Sengupta
Journal:  Mol Biol Rep       Date:  2021-03-31       Impact factor: 2.316

Review 3.  The role of RNA-binding protein tristetraprolin in cancer and immunity.

Authors:  Jian Guo; Huiheng Qu; Ye Chen; Jiazeng Xia
Journal:  Med Oncol       Date:  2017-11-09       Impact factor: 3.064

Review 4.  Dysregulation of TTP and HuR plays an important role in cancers.

Authors:  Hao Wang; Nannan Ding; Jian Guo; Jiazeng Xia; Yulan Ruan
Journal:  Tumour Biol       Date:  2016-09-19

5.  Inactivation of tristetraprolin in chronic hypoxia provokes the expression of cathepsin B.

Authors:  Dominik C Fuhrmann; Michaela Tausendschön; Ilka Wittig; Mirco Steger; Martina G Ding; Tobias Schmid; Nathalie Dehne; Bernhard Brüne
Journal:  Mol Cell Biol       Date:  2014-12-01       Impact factor: 4.272

Review 6.  Reviewing and reconsidering invasion assays in head and neck cancer.

Authors:  Ronald C Inglehart; Christina S Scanlon; Nisha J D'Silva
Journal:  Oral Oncol       Date:  2014-10-14       Impact factor: 5.337

7.  Enhanced LPS-induced peritonitis in mice deficiency of cullin 4B in macrophages.

Authors:  M-H Hung; Y-R Jian; C-C Tsao; S-W Lin; Y-H Chuang
Journal:  Genes Immun       Date:  2014-06-05       Impact factor: 2.676

8.  The Histone Methyltransferase EZH2 Mediates Tumor Progression on the Chick Chorioallantoic Membrane Assay, a Novel Model of Head and Neck Squamous Cell Carcinoma.

Authors:  Min Liu; Christina Springstead Scanlon; Rajat Banerjee; Nickole Russo; Ronald C Inglehart; Amanda L Willis; Stephen J Weiss; Nisha J D'Silva
Journal:  Transl Oncol       Date:  2013-06-01       Impact factor: 4.243

9.  IL-6/NOS2 inflammatory signals regulate MMP-9 and MMP-2 activity and disease outcome in nasopharyngeal carcinoma patients.

Authors:  Ahmed-Amine Zergoun; Abderezak Zebboudj; Sarah Leila Sellam; Nora Kariche; Djamel Djennaoui; Samir Ouraghi; Esma Kerboua; Zine-Charaf Amir-Tidadini; Dalia Chilla; Fatima Asselah; Chafia Touil-Boukoffa; Taha Merghoub; Mehdi Bourouba
Journal:  Tumour Biol       Date:  2015-10-09

10.  Characterization of squamous cell carcinoma in an organotypic culture via subsurface non-linear optical molecular imaging.

Authors:  Christina S Scanlon; Elizabeth A Van Tubergen; Leng-Chun Chen; Sakib F Elahi; Shiuhyang Kuo; Stephen Feinberg; Mary-Ann Mycek; Nisha J D'Silva
Journal:  Exp Biol Med (Maywood)       Date:  2013-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.